<DOC>
	<DOCNO>NCT00865709</DOCNO>
	<brief_summary>To determine sorafenib added chemotherapy slow disease progression chemotherapy alone patient previously untreated metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Modified FOLFOX6 Plus Minus Sorafenib Stage IV Metastatic Colorectal Carcinoma ( mCRC ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histological confirmation adenocarcinoma colon rectum Tumor tissue sample available KRAS BRAF assessment Measurable metastatic Stage IV disease include least one measurable lesion previously radiate No prior chemotherapy metastatic CRC Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Life expectancy least 12 week Adequate bone marrow , liver , renal function ; adequate clotting parameter Prior treatment sorafenib Clinical radiographic evidence brain metastasis Major surgery , surgical biopsy , significant traumatic injury within 28 day randomization ; evidence history bleed diathesis coagulopathy Red blood cell ( RBC ) , white blood cell ( WBC ) , platelet transfusion and/or growth factor use within 28 day randomization Adjuvant therapy CRC ( Stage I , II , III ) complete within 12 month randomization Serious , nonhealing wound , ulcer , bone fracture ; Grade 3 4 hemorrhage within 28 day randomization Use anticoagulation therapy ( low dose anticoagulation therapy mitigate risk thrombosis due placement semipermanent central venous port administration chemotherapy allow . The use coumadin related compound exclude . ) Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg repeat measurement ) despite optimal medical management Thrombolic , embolic , venous , arterial event ( eg , cerebrovascular accident , include transient ischemic attack ) within 6 month randomization Active cardiac disease include : Congestive heart failure Unstable angina myocardial infarction within 6 month randomization Cardiac ventricular arrhythmia require antiarrhythmic treatment Peripheral neuropathy &gt; Grade 1 ( CTCAE ) Known HIV infection chronic hepatitis B C infection Any active infection &gt; /= Grade 2 ( CTCAE ) Any medical , psychological , social condition may interfere subject 's participation study evaluation study result Use investigational drug within 28 day 5 halflives drug , whichever longer , randomization Subjects metastatic CRC currently candidate surgery curative intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Liver Metastasis</keyword>
</DOC>